Entera Bio Ltd. — Form 8-K
Filed October 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 38/100
What the filing says
Entera Bio appointed biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026, replacing Yonatan Malca after 16 years of service. Hamill brings 35+ years of commercial experience, most recently as EVP Worldwide Commercial Operations at Gilead (managing $22B revenue and ~2,500 employees) and prior senior roles at Amgen. She currently serves on boards of Jazz Pharmaceuticals, BB Biotech, and Fate Therapeutics. No compensation or equity details disclosed in filing.
Why this rating
Board composition change adds credible commercial expertise ahead of EB613 Phase 3 and potential commercialization. Meaningful for pre-commercial biotech, but routine board succession with no direct financial impact or capital raise. Non-material relative to $84.6M market cap.
See more from October 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.